Delving into the Latest Updates on Litevax B V with Synapse

Overview

Tags

Infectious Diseases

Respiratory Diseases

Neoplasms

Prophylactic vaccine

Therapeutic vaccine

Inactivated vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	3
Neoplasms	1

Top 5 Drug Type	Count

Prophylactic vaccine	3
Inactivated vaccine	1
Therapeutic vaccine	1

Top 5 Target	Count

HER2(Receptor tyrosine-protein kinase erbB-2)	1

The effect of LiteVax Adjuvant supplemented to licensed seasonal influenza vaccine on safety and immunogenicity will be investigated in both younger and older healthy participants. Local and systemic adverse events, and humoral and cellular immune responses will be determined at different time intervals after a single administration. Mode of action of LiteVax Adjuvant will examined by detailed genetic analysis and omics approaches such as transcriptomics, proteomics and metabolomics.

Start Date29 Jan 2024

Sponsor / Collaborator

Litevax B V

NCT05581407

/ CompletedPhase 1

A Randomized First-in-human, Observer-blind, 3-arm Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single Administration of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccine

There is an obvious need for an affordable and more effective seasonal influenza vaccine. TETRALITE is a novel, inactivated, adjuvanted influenza vaccine combining a low dose of a licensed vaccine with the novel, potent LiteVax Adjuvant.
A licensed vaccine (Cohort 1) with a normal dose [15 ug per strain] and no adjuvant will be compared with two TETRALITE study vaccines with 1/5th of the licensed vaccine added with a low (Cohort 2) or high (Cohort 3) dose of LiteVax Adjuvant.

Start Date03 Oct 2022

Sponsor / Collaborator

Litevax B V

[+1]

100 Clinical Results associated with Litevax B V

Login to view more data

0 Patents (Medical) associated with Litevax B V

Login to view more data

100 Deals associated with Litevax B V

Login to view more data

100 Translational Medicine associated with Litevax B V

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

1

Phase 2 Clinical

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Inactivated adjuvanted influenza vaccine(LiteVax)	Influenza, Human More	Phase 2 Clinical
BACTOVAC (Litevax)	Clostridium difficile infection More	Preclinical
COROVAC-LITE (Litevax)	COVID-19 More	Preclinical
TREAT-HER2 (Litevax) ( HER2 )	Breast Cancer More	Preclinical
TATX-99	COVID-19 More	Discontinued